PAK4 and nonpapillary renal cell carcinoma: In terms of clinical implications, the elevated expression of PAK4 is associated with early recurrence and reduced survival rates in patients with nonmetastatic CCRCC, particularly those classified as low-risk following nephrectomy [53].